Home Trials Genes Drugs 23andMe Graph Blog Contact

Home
Trials
Genes
Drugs
23andMe
Graph
Blog
Contact

Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

ClinicalTrials.gov
OpenTargets
ClinVar
PubChem

Links

Contact
About
Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

NCT05619367 - A Compassionate Use (CU) Program of Odronextamab | Crick | Crick

A Compassionate Use (CU) Program of Odronextamab

N/AAvailableNCT05619367

Regeneron Pharmaceuticals

Overview

Provide compassionate use of odronextamab

Study Type

EXPANDED_ACCESS

Conditions

Relapsed or Refractory (R/R) Follicular Lymphoma (FL)Diffuse Large B-Cell Lymphoma (DLBCL)B-Cell Non-Hodgkin Lymphoma (NHL)High-Grade B-Cell Lymphoma (HGBCL)

Interventions

OdronextamabDRUG

Central Contacts

Requests for compassionate use must be initiated by a treating physician Physicians should contact

CONTACT

844-734-6643 CompassionateUseRequests@regeneron.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.